A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness
- 15 August 2005
- journal article
- research article
- Published by Elsevier BV in Regulatory Peptides
- Vol. 130 (1-2), 1-6
- https://doi.org/10.1016/j.regpep.2005.05.001
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs, 2004
- Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 DiabetesJournal of Medicinal Chemistry, 2004
- A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptorsBritish Journal of Pharmacology, 2003
- International Union of Pharmacology. XXXV. The Glucagon Receptor FamilyPharmacological Reviews, 2003
- Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1Diabetes/Metabolism Research and Reviews, 2002
- Selective Ligand-induced Stabilization of Active and Desensitized Parathyroid Hormone Type 1 Receptor ConformationsPublished by Elsevier BV ,2002
- Characterization of glucagon-like peptide-1 receptor-binding determinantsJournal of Molecular Endocrinology, 2000
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Glucagon-like peptidesDiabetes, 1998
- Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptorDiabetes, 1993